



30 April 2024

## Byotrol plc

("Byotrol" or the "Company")

### Admission Statement

The Board of Byotrol plc, the specialist infection prevention and control company is pleased to announce the admission of its Ordinary Shares to trading on Asset Match ahead of its first auction.

It is intended that the first auction in the Company's shares will be held in June 2024. Thereafter, auctions are expected to be held every quarter. More information, including exact auction dates and details on how to buy and sell, are available on the company profile [page](#).

#### The directors of the Company are:

David Traynor (*Interim Chief Executive Officer*)

Chris Sedwell (*Chief Financial Officer*)

Ashley Head (*Non-Executive Chairman*)

Dr Trevor Francis (*Non-Executive Director*)

Sean Gogarty (*Non-Executive Director*)

#### Registered office:

Riverside Works, Collyhurst Road, Manchester M40 7RU.

#### David Traynor, Interim Chief Executive Officer of Byotrol plc, commented:

"The Board is very pleased to be working with Asset Match to provide ongoing liquidity for our shareholders following our delisting from the Alternative Investment Market ("AIM") of the LSE in April 2024."

#### 1. Company Description

**Byotrol plc** is a specialist infection prevention and control company, operating globally in the Animal and Human Healthcare sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae. Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, within increasingly stringent regulatory environments.

#### 2. Strategy and Prospects

Byotrol's long-term strategy has been to build an IP-based biocide technology company, founded on strong science, regulatory approvals and segmental expertise, generating sustainable profits from its own product sales and from monetizing IP.

The last two years have seen the business pivoting towards break-even from its product sales operation, leaning on its specialism within our chosen primary market of animal health, complemented by focus in specific niche areas of human health. Over this time, which has seen an extended period of disruption and volatility in our markets post the short financial boom from the Covid pandemic, we have improved operational KPIs significantly, including a step-change in our achieved gross margins.

Concurrently, the business has invested heavily in R&D to develop and deliver new formulations that are future-proofed against upcoming changes in both the UK and EU regulatory environments, leaving it well placed to capitalize on its position as new regulations come into place, and as other less well-positioned competitors are expected to fall away.

Our near-term focus is to use the knowledge, expertise and brand equity we have developed within the UK marketplace to springboard into the EU and adjacent animal health markets, through a combination of organic and inorganic growth. In turn, this will deliver break-even and then the sustained profitability that our shareholders are demanding, with the monetization of our outstanding IP portfolio providing an additional source of funds to re-invest in both the operational and developmental capabilities of Byotrol.

### **3. Board of Directors**

Brief biographies of the directors of the Company are set out below.

#### **David Traynor – Interim Chief Executive Officer**

David began his career in 1987 in investment banking, working in corporate finance roles for Credit Suisse First Boston, UBS and Lehman Brothers. In 2003 he moved to WhatIf Ventures, the investment arm of the innovation company WhatIf, where he specialised in commercialising new products and technologies in markets including UK annuities, high street retail, fast food and innovative polymers. Prior to becoming CEO at Byotrol plc, David ran Byotrol Consumer Products (BCP) from its inception in 2007 within his partnership role at WhatIf Ventures, moving to full time early 2012. He led BCP to profitability in 2011 and then to the full acquisition by Byotrol plc in October 2013. David has an MBA from London Business School and a BA from Oxford University.

#### **Chris Sedwell – Chief Financial Officer**

Chris began his financial career at Deloitte, qualifying as an ACA in 2003. Prior to joining Byotrol in December 2021, he was a Portfolio Finance Director with The FD & CFO Centre, working with numerous SMEs to provide finance consultancy, and improve reporting systems and processes. For the preceding six years, he was Finance Director of ConvaTec Limited, a FTSE 250 listed medical products and technologies business. Prior to this, he was Head of Finance & Administration at Iceland International, a part of the UK supermarket chain Iceland Foods Group.

#### **Ashley Head – Non-Executive Chairman**

Ashley joined the Board of Byotrol in September 2023 as a Non-Executive Director, becoming Non-Executive Chairman in April 2024. He began his career with Chase Manhattan Bank, where he rose through the ranks of technology and online banking. He then joined MasterCard, where he became responsible for the African region of the group. After recognising the opportunities within eCommerce Ashley founded Proc Cyber, growing the business to a valuation of over £60 million in three years and then merging with Datacash in 2006 where he assumed the role of Chairman. Under Ashley's leadership, Datacash grew to a market-leading position with MasterCard purchasing the company in 2010. Ashley continues to lead a vibrant portfolio career and currently serves as Chairman of The AI Corporation, MySense Group, Ocean Harvest Technology Group, and Champagne Piaff in addition to other director positions. Ashley is also a trustee for the National Emergency Trust, Epsom College, and Stonegate Foundation.

#### **Dr Trevor Francis – Non-Executive Director**

Trevor's career at Unilever spanned 29 years, initially in Manufacturing and that included 3 years as Production Director in Cote D'Ivoire, The second half of Trevor's career at Unilever was spent in a number of Research and Development roles that culminated as Global VP R & D Homecare in 2001. During Trevor's period in R & D, he managed teams that brought a number of successful innovations to the market place. Trevor was also a principal driver in developing a progressive approach to Fragrance Management. After Unilever, Trevor established a management consultancy business, working with a number of consumer and

chemical companies, before starting work as a consultant with Byotrol Consumer Products (BCP) not long after its inception. Trevor is a graduate in Applied Chemistry of Queen’s University, Belfast and following completion of his Ph.D. at Queen’s he worked under Professor Zahn as a Post-Doctoral Fellow at DWI Aachen, Germany.

#### **Sean Gogarty – Non-Executive Director**

Sean spent 20 years of his career at Unilever, where his roles included Global Divisional CEO of Unilever Baking, Cooking and Spreads, and Global Category EVP for Household Care. In the latter role, he led the rapid growth of a number of well-known household brands, including Domestos, Cif, Lysoform and Sunlight, from a sales value of €800m to over €2.5bn. Sean also has a strong track record of advising a range of leading private equity firms and companies on the development of business strategies, brand portfolio plans, organisational structures and supply chain strategies. He also acts as a Non-executive Director at Slicethepie Ltd. Sean has a BSc in Economics from University College London.

#### **4. Share capital and significant shareholders**

At 30 April 2024 the Company’s issued share capital consisted of 453,890,405 Ordinary Shares with a nominal value of 0.01p each, each share having equal voting rights, and 453,890,405 Deferred shares with a nominal value of 0.24p each. The Deferred shares do not hold voting rights.

The Company does not hold any Ordinary Shares in treasury and therefore the number of Ordinary Shares with voting rights is 453,890,405.

The Ordinary Shares are not admitted to trading on any exchange or trading platform other than Asset Match, having exited the Alternative Investment Market (“AIM”) of the London Stock Exchange (“LSE”) effective 30 April 2024.

The Company has been notified that the following shareholder(s) are interested in 3% or more of the issued share capital of the company:

<i>Name of shareholder</i>	<i>Number of Ordinary Shares</i>	<i>Percentage holding</i>
Directors	25,099,028	5.53%
Amati Global Investors	25,000,001	5.51%
Bottomley Family	18,450,000	4.06%
Mr G Watson	16,500,000	3.64%
Mr C Weatherhead	15,784,000	3.48%
Redmayne Bentley Stockbrokers	15,767,867	3.47%
Tonex Holdings	15,251,538	3.36%

#### **5. Financial statements**

The Company’s latest Interim Report and Accounts for the six month’s to 30 September 2023 can be accessed on the company profile [page](#).

#### **6. Legal and Arbitration Proceedings**

During the 12 months preceding the date of this document, neither the Company nor any of its subsidiaries has been engaged in or is currently engaged in any litigation or arbitration proceedings which have or may have had in the recent past a significant effect on the financial position of the Company and so far as the directors are aware, there are no such proceedings pending or threatened by or against the Company or any of its subsidiaries.

## **7. Responsibility Statement**

The directors of Byotrol plc, as set about above, accept responsibility for the information contained within this document. To the best of the knowledge and belief of the directors (who have taken reasonable care to ensure that such is the case) the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information.

**REMINDER:** It is intended that the first auction in the Company's shares will be held in **June 2024**. Thereafter, auctions will be held at regular intervals. More information, including exact auction dates and details on how to buy and sell, will be provided in due course.

-- ENDS --